MA50173A - Composés activateurs de bisamide sarcomère et leurs utilisations - Google Patents
Composés activateurs de bisamide sarcomère et leurs utilisationsInfo
- Publication number
- MA50173A MA50173A MA050173A MA50173A MA50173A MA 50173 A MA50173 A MA 50173A MA 050173 A MA050173 A MA 050173A MA 50173 A MA50173 A MA 50173A MA 50173 A MA50173 A MA 50173A
- Authority
- MA
- Morocco
- Prior art keywords
- sarcomeric
- bisamide
- activator compounds
- activator
- compounds
- Prior art date
Links
- 239000012190 activator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- FTQWRYSLUYAIRQ-UHFFFAOYSA-N n-[(octadecanoylamino)methyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCNC(=O)CCCCCCCCCCCCCCCCC FTQWRYSLUYAIRQ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762557846P | 2017-09-13 | 2017-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50173A true MA50173A (fr) | 2020-07-29 |
Family
ID=63794635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050173A MA50173A (fr) | 2017-09-13 | 2018-09-13 | Composés activateurs de bisamide sarcomère et leurs utilisations |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US10723720B2 (fr) |
| EP (1) | EP3681882A1 (fr) |
| JP (1) | JP7308816B2 (fr) |
| KR (1) | KR20200054237A (fr) |
| CN (1) | CN111601798B (fr) |
| AR (1) | AR112804A1 (fr) |
| AU (1) | AU2018332887B2 (fr) |
| BR (1) | BR112020004800A2 (fr) |
| CA (1) | CA3075669A1 (fr) |
| CL (1) | CL2020000610A1 (fr) |
| CO (1) | CO2020002745A2 (fr) |
| CR (1) | CR20200116A (fr) |
| EA (1) | EA202090688A1 (fr) |
| IL (1) | IL272573B2 (fr) |
| JO (1) | JOP20200059A1 (fr) |
| MA (1) | MA50173A (fr) |
| MX (2) | MX2020002696A (fr) |
| PE (1) | PE20200924A1 (fr) |
| PH (1) | PH12020500446A1 (fr) |
| SA (1) | SA520411524B1 (fr) |
| SG (1) | SG11202001377PA (fr) |
| TW (1) | TWI790281B (fr) |
| UY (1) | UY37879A (fr) |
| WO (1) | WO2019055590A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202090688A1 (ru) | 2017-09-13 | 2020-07-06 | Эмджен Инк. | Бис-амидные соединения, активирующие саркомер, и варианты их применения |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| KR20210016545A (ko) * | 2018-05-29 | 2021-02-16 | 오메로스 코포레이션 | Masp-2 억제제 및 사용 방법 |
| AU2020234995A1 (en) * | 2019-03-12 | 2021-10-21 | Amgen Inc. | Polymorphs and cocrystals of a cardiac troponin activator |
| CN114025845A (zh) * | 2019-03-12 | 2022-02-08 | 安进股份有限公司 | 心肌肌钙蛋白活化剂的多晶型物 |
| PH12022550179A1 (en) * | 2019-07-23 | 2022-11-14 | Bayer Ag | Novel heteroaryl-triazole compounds as pesticides |
| WO2021113682A1 (fr) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Inhibiteurs de masp-2 et procédés d'utilisation |
| EP4069676A1 (fr) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Inhibiteurs de masp-2 et procédés d'utilisation |
| EP4069678A1 (fr) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Inhibiteurs de masp-2 et procédés d'utilisation |
| WO2021113686A1 (fr) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Inhibiteurs de masp-2 et procédés d'utilisation |
| IL299180A (en) * | 2020-06-17 | 2023-02-01 | Merck Sharp & Dohme Llc | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS |
| MX2023009857A (es) | 2021-03-15 | 2024-01-03 | Maze Therapeutics Inc | Inhibidores de la glucogeno sintasa 1 (gys1) y metodos de uso de los mismos. |
| WO2023122325A2 (fr) * | 2021-12-23 | 2023-06-29 | Regents Of The University Of Michigan | Composés méta-anilides et procédés d'utilisation associés pour traiter des maladies et des troubles |
| IL319671A (en) | 2022-09-26 | 2025-05-01 | Edgewise Therapeutics Inc | 4,1-Dihydroquinazolinone compounds and their uses |
| EP4688756A1 (fr) | 2023-03-27 | 2026-02-11 | Edgewise Therapeutics, Inc. | Composés de quinazoline dione et leurs utilisations |
| CN121194963A (zh) | 2023-03-27 | 2025-12-23 | 艾知怀斯治疗学公司 | 喹啉酮酰胺类化合物及其用途 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0662529B2 (ja) * | 1984-07-13 | 1994-08-17 | 三共株式会社 | アミノ酸誘導体 |
| US5952307A (en) | 1994-01-21 | 1999-09-14 | Georgia Tech Research Corp. | Basic α-aminoalkylphosphonate derivatives |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| GB9708119D0 (en) | 1997-04-22 | 1997-06-11 | Glaxo Group Ltd | Chemical compounds |
| AU1082901A (en) | 1999-10-18 | 2001-04-30 | National Jewish Medical And Research Center | Method for modulation of cell phenotype |
| US20010049373A1 (en) | 2000-01-28 | 2001-12-06 | Chalquest Richard R. | Materials and methods for killing nematodes and nematode eggs |
| EP1125925A1 (fr) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Dérivés amines pour le traitement de l'apoptose |
| US6495337B1 (en) | 2000-03-29 | 2002-12-17 | Cytokinetics, Inc. | High throughput sarcomeric assay |
| AU2002237733A1 (en) | 2000-11-07 | 2002-06-18 | Board Of Regents, The University Of Texas System | Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| AU2002367023A1 (en) | 2001-12-21 | 2003-07-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| AU2002365057A1 (en) | 2001-12-21 | 2003-07-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| US7399866B2 (en) | 2003-01-14 | 2008-07-15 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| EP1605752B1 (fr) | 2003-03-27 | 2011-09-14 | Cytokinetics, Inc. | Sulfonamides pour le traitment de l' insuffisance cardiaque congestive, leur compositions et utilisations. |
| WO2004094610A2 (fr) | 2003-04-21 | 2004-11-04 | Baylor College Of Medicine | Wnt utilise comme facteur pour la myogenese cardiaque |
| US7541466B2 (en) | 2003-12-23 | 2009-06-02 | Genzyme Corporation | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases |
| JP2005298628A (ja) | 2004-04-09 | 2005-10-27 | Sumitomo Chemical Co Ltd | オレフィン重合触媒成分及びオレフィン重合体の製造方法 |
| MXPA06014495A (es) | 2004-06-17 | 2007-03-01 | Cytokinetics Inc | Compuestos, composiciones y metodos. |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US20070208000A1 (en) | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| TW200808321A (en) | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| EP1959962A2 (fr) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Entites chimiques, compositions et methodes |
| US7989455B2 (en) | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2007089805A2 (fr) | 2006-01-31 | 2007-08-09 | The General Hospital Corporation | Effets anti-hypertrophiques et effets inotropiques d'une picot |
| US20080227823A1 (en) | 2007-03-12 | 2008-09-18 | Hassan Pajouhesh | Amide derivatives as calcium channel blockers |
| GB0708818D0 (en) | 2007-05-08 | 2007-06-13 | Portela & Ca Sa | Compounds |
| US20090192168A1 (en) * | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| JP2014534206A (ja) | 2011-10-17 | 2014-12-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｃ型肝炎ウイルス阻害剤 |
| WO2013106646A2 (fr) | 2012-01-12 | 2013-07-18 | Yale University | Composés et procédés pour l'inhibition de l'ubiquitine ligase vcb e3 |
| RU2666530C2 (ru) * | 2012-01-12 | 2018-09-11 | Йейл Юниверсити | Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы |
| CA2902424A1 (fr) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Composes heterocycliques et leurs utilisations |
| WO2015103527A1 (fr) | 2014-01-06 | 2015-07-09 | The Scripps Research Institute | Modulateurs de rev-erb |
| WO2015142001A2 (fr) | 2014-03-21 | 2015-09-24 | 충남대학교산학협력단 | Composé doté d'une action cardiotonique et composition pharmaceutique permettant de prévenir ou de traiter l'insuffisance cardiaque et contenant ledit composé |
| KR102585550B1 (ko) | 2015-01-22 | 2023-10-10 | 미요카디아, 인크. | 확장성 심근병증 (dcm)의 치료를 위한 4-메틸술포닐-치환된 피페리딘 우레아 화합물 |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| WO2016201288A1 (fr) | 2015-06-12 | 2016-12-15 | Brown University | Nouveaux composés antibactériens et procédés de préparation et d'utilisation de ceux-ci |
| KR101766731B1 (ko) | 2015-06-23 | 2017-08-10 | 충남대학교산학협력단 | 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물 |
| US10543215B2 (en) | 2015-06-26 | 2020-01-28 | Amgen Inc. | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| KR20160108281A (ko) | 2016-09-06 | 2016-09-19 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
| TWI769272B (zh) | 2017-06-30 | 2022-07-01 | 美商安進公司 | 奧美卡替莫卡必爾的合成 |
| EA202090688A1 (ru) | 2017-09-13 | 2020-07-06 | Эмджен Инк. | Бис-амидные соединения, активирующие саркомер, и варианты их применения |
| EP3594199B1 (fr) | 2018-07-09 | 2020-07-01 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | 2-fluoro-3-nitrotoluène cristallin et son procédé de préparation |
| JP2021534138A (ja) | 2018-08-17 | 2021-12-09 | アムジエン・インコーポレーテツド | オメカムチブメカルビルの塩及び結晶形態 |
| WO2020131574A1 (fr) | 2018-12-18 | 2020-06-25 | Amgen Inc. | Procédé de réduction de composés nitro aromatiques |
| CN114025845A (zh) | 2019-03-12 | 2022-02-08 | 安进股份有限公司 | 心肌肌钙蛋白活化剂的多晶型物 |
| AU2020234995A1 (en) | 2019-03-12 | 2021-10-21 | Amgen Inc. | Polymorphs and cocrystals of a cardiac troponin activator |
-
2018
- 2018-09-13 EA EA202090688A patent/EA202090688A1/ru unknown
- 2018-09-13 WO PCT/US2018/050793 patent/WO2019055590A1/fr not_active Ceased
- 2018-09-13 KR KR1020207010115A patent/KR20200054237A/ko not_active Abandoned
- 2018-09-13 CN CN201880072907.5A patent/CN111601798B/zh active Active
- 2018-09-13 JO JOP/2020/0059A patent/JOP20200059A1/ar unknown
- 2018-09-13 PE PE2020000339A patent/PE20200924A1/es unknown
- 2018-09-13 US US16/129,862 patent/US10723720B2/en active Active
- 2018-09-13 AR ARP180102603A patent/AR112804A1/es unknown
- 2018-09-13 SG SG11202001377PA patent/SG11202001377PA/en unknown
- 2018-09-13 JP JP2020514579A patent/JP7308816B2/ja active Active
- 2018-09-13 CA CA3075669A patent/CA3075669A1/fr active Pending
- 2018-09-13 TW TW107132171A patent/TWI790281B/zh active
- 2018-09-13 EP EP18783202.7A patent/EP3681882A1/fr not_active Withdrawn
- 2018-09-13 IL IL272573A patent/IL272573B2/en unknown
- 2018-09-13 UY UY0001037879A patent/UY37879A/es not_active Application Discontinuation
- 2018-09-13 CR CR20200116A patent/CR20200116A/es unknown
- 2018-09-13 AU AU2018332887A patent/AU2018332887B2/en not_active Ceased
- 2018-09-13 BR BR112020004800-3A patent/BR112020004800A2/pt not_active Application Discontinuation
- 2018-09-13 MA MA050173A patent/MA50173A/fr unknown
- 2018-09-13 MX MX2020002696A patent/MX2020002696A/es unknown
-
2020
- 2020-03-05 PH PH12020500446A patent/PH12020500446A1/en unknown
- 2020-03-10 CL CL2020000610A patent/CL2020000610A1/es unknown
- 2020-03-10 MX MX2022014864A patent/MX2022014864A/es unknown
- 2020-03-10 CO CONC2020/0002745A patent/CO2020002745A2/es unknown
- 2020-03-12 SA SA520411524A patent/SA520411524B1/ar unknown
- 2020-03-27 US US16/833,321 patent/US11254658B2/en active Active
- 2020-03-27 US US16/833,336 patent/US10899746B2/en active Active
- 2020-10-12 US US17/068,518 patent/US11299479B1/en active Active
-
2022
- 2022-02-15 US US17/672,594 patent/US11780826B2/en active Active
-
2023
- 2023-08-17 US US18/451,757 patent/US20240158372A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50173A (fr) | Composés activateurs de bisamide sarcomère et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| EP3694861A4 (fr) | Composés hétérocycliques et leurs utilisations | |
| EP3917529A4 (fr) | Composés et leurs utilisations | |
| EP3787607A4 (fr) | Compositions de caroténoïdes et leurs utilisations | |
| EP3917527A4 (fr) | Composés et leurs utilisations | |
| MA52365A (fr) | Composés et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3849983A4 (fr) | Composés de triazolo-pyrimidine et leurs utilisations | |
| EP3768269A4 (fr) | Composés et leurs utilisations | |
| EP3337486A4 (fr) | Composés deutérés et leurs utilisations | |
| MA55385A (fr) | Composés et leurs utilisations | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| EP3313530A4 (fr) | Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci | |
| EP3790883A4 (fr) | Composés hétéroaryles et leurs utilisations | |
| EP3902530A4 (fr) | Nanovaccins polymères et leurs utilisations | |
| EP3494119A4 (fr) | Composés et compositions, et utilisations associées | |
| EP3700934A4 (fr) | Composés et utilisations de ces composés | |
| EP3880194A4 (fr) | Composés deutérés, compositions et utilisations | |
| EP3841096A4 (fr) | Dérivés de pyridinylméthylènepipéridine et leurs utilisations | |
| EP3838900A4 (fr) | Composés de 3-aryloxy-3-aryl-propylamine et utilisations associées | |
| MA48956A (fr) | Composés mic-1 et utilisations associées | |
| EP3450444A4 (fr) | Composés de type crocine et utilisations correspondantes | |
| EP3323817A4 (fr) | Dérivés d'aniline pyrimidine et leurs utilisations | |
| EP3914593A4 (fr) | Composés et leurs utilisations |